07 - 09 September, 2010, Hilton Munich Park, Munich, Germany
Download the Brochure
Podcast
Articles
Presentations
Become a Pharma IQ Member and receive our weekly newsletter!
Learn more about sponsor & exhibit opportunities
Mark Your Calendar
Tell a Colleague
The area of BioPatent Design is one that is rapidly evolving, with new developments sparking the Gene debate, developments in Biosimilars, protection issues with regards to DNA sequencing patents, vaccines and stem cells as well as new guidelines issued from the EPO. This is a critical time to make the correct patent drafting decisions! Pharma IQ’s BioPatent Design conference is your chance to address some of these issues, with internationally renowned representatives sharing their best practices and expertise, coupled with 10+ networking opportunities.
Very good selection of speakers from all relevant areas of expertise!
It’s been very good, the subject matter was useful, all of the speakers came across as well informed. The spectrum of topics was excellent.
See our Agenda-at-a-glance for more information on which speakers and sessions can answer your specific challenges.
Ensuring First Time Approval for Biotech Invention Patents: The USPTO Perspective David Kappos Director, IP Group USPTO
Understanding the Recent EPO’s Standards and Rule Changes and the Ultimate Impact on Your Business John Beatty Patent Procedures Management European Patent Office
Multi Jurisdictional Patent Office Approval Standards
John Beatty Patent Procedures Management European Patent Office
Lawrence Cullen Deputy Director IPO
Dr Roman Maksymiw Head of Division, German Patent and Trademark Office DPMA
Trends for Biopatents at German Patent and Trademark Office Dr Roman Maksymiw Head of Division, German Patent and Trademark Office DPMA
Ensuring First Time Approval for Biotech Invention Patents
Exclusivity Extensions: Opportunities and Limits of Employing SPC’s and Paediatric Extensions to Maximise Protection
Peter Thomsen Sr. Manager IP-Litigation and Global Head IP-Policy Novartis International AG
The Current State of the New European Bolar-Type Provisions
Martin Sperrle VP and CIPO Cytos Biotechnology
The Consequences for Biotech Patenting of the European Union Patent and Litigation System
Rob Aerts Principal Patent Attorney Abbott Healthcare Products B.V.
Developing a Robust Patenting Strategy on a Per Product/Project Basis
Morten Rosted Head of Department, DK Patents, Corporate Patents & Trademarks H. Lundbeck A/S
Rolling Out a Global Patent Strategy for Biological Drugs
Biogenerics and Biosimilars: At the Interface Between Patents and Data Exclusivity
Frank Landolt Intellectual Property and Legal Counsel Albynx
Strategies for Global Protection of Therapeutic Antibodies Today and Tomorrow
Dr Scott Alban Associate General Counsel, Head of Intellectual Property MedImmune LLC
Obtaining Meaningful Therapeutic Antibody Claims in the New Millennium
Vineet Kohli Assistant Counsel, Patent Merck
Assessing Patentability of Mature and Growth Areas of Pharmaceutical Patents: Diabetes vs Stem Cells
Lars Balzer Nielsen Director, Diabetes Patents, Corporate Patents Novo Nordisk A/S
Patent Protection for Gene Sequences
Ian Bryan IP Counsel GE Healthcare
Recent Biotech Case Law Decisions and the Impact on the Industry
Andre Bourgouin VP, Intellectual Property Ipsen
Located in the heart of Munich, this is the perfect platform for you to:
Download the full agenda.
Companies
Representatives from in-house counsel:
Representatives from external counsel:
[ Register Now ]